Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 76

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 76
---
 and worldwide economy; the timing, scope and effectiveness of United States, United Kingdom and international governmental response; and the impact on the health, well-being and productivity of our employees. To the extent that pandemics or disease outbreak, such the COVID-19 pandemic, adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this “ Risk Factors” section.

Risks related to our intellectual property

Our success depends in part on our ability to protect rights in our intellectual property, which cannot be assured.

Our success and ability to
compete effectively are in large part dependent upon exploitation of proprietary technologies and products that we have developed internally
or have acquired or in-licensed. To date, we have relied on copyright, trademark and trade secret laws, as well as confidentiality procedures,
non-compete and/or work for hire invention assignment agreements and licensing arrangements with our employees, consultants, contractors,
customers and vendors, to establish and protect our rights to our technology and, to the best extent possible, control the access to and
distribution of our technology, software, documentation and other proprietary information, all of which offer only limited protection.
Where we have the right to do so under our agreements, we seek to protect our proprietary position by filing patent applications in the
United States, the United Kingdom and worldwide related to our novel technologies and products that are important to our business. The
patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions
and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial
value of our patents, including those patent rights licensed to us by third parties, are highly uncertain. There can be no assurance that:

| • | the scope of our patents provides and will provide us with exclusivity with respect to any or all of our                                  
 product candidates and technologies, as well as any other technologies and/or products that address the same problems as our technologies 
 and product candidates by a different means, whether in the same manner as us or not;                                                     |

| • | pending or future patent applications will be issued as patents; |

| • | our patents, and/or those patents to which we are licensed, are and will remain valid and enforceable                                   
 and will not be subject to invalidity or revocation proceedings and that such proceedings will not result in a complete or partial loss 
 of rights;                                                                                                                              |

| • | our entitlement